Diagnosis, Risk Category, and HLA Disparity at Time of PMRD allo-BMT
| Patients . | Low Risk . | High Risk . |
|---|---|---|
| n = 72 | 20 (28%)* | 52 (72%) |
| Diagnosis | ||
| ALL | 10 (14%) | 18 (25%) |
| AML | 3 (4%) | 16 (22%) |
| CML/CLL | 5 (7%) | 14 (19%) |
| SAA/MDS | 2 (3%) | 4 (6%) |
| Disease-status linked to degree of HLA disparity | ||
| Donor mismatch (rejection direction)† | ||
| 1 antigen (n = 13) | 4 (6%) | 9 (13%) |
| 2 antigen (n = 35) | 13 (18%) | 22 (31%) |
| 3 antigen (n = 24) | 3 (4%) | 21 (29%) |
| Recipient mismatch (GVHD direction)‡ | ||
| 1 antigen (n = 11) | 5 (7%) | 6 (8%) |
| 2 antigen (n = 30) | 9 (13%) | 21 (29%) |
| 3 antigen (n = 31) | 6 (8%) | 25 (35%) |
| Patients . | Low Risk . | High Risk . |
|---|---|---|
| n = 72 | 20 (28%)* | 52 (72%) |
| Diagnosis | ||
| ALL | 10 (14%) | 18 (25%) |
| AML | 3 (4%) | 16 (22%) |
| CML/CLL | 5 (7%) | 14 (19%) |
| SAA/MDS | 2 (3%) | 4 (6%) |
| Disease-status linked to degree of HLA disparity | ||
| Donor mismatch (rejection direction)† | ||
| 1 antigen (n = 13) | 4 (6%) | 9 (13%) |
| 2 antigen (n = 35) | 13 (18%) | 22 (31%) |
| 3 antigen (n = 24) | 3 (4%) | 21 (29%) |
| Recipient mismatch (GVHD direction)‡ | ||
| 1 antigen (n = 11) | 5 (7%) | 6 (8%) |
| 2 antigen (n = 30) | 9 (13%) | 21 (29%) |
| 3 antigen (n = 31) | 6 (8%) | 25 (35%) |
Abbreviations: n, number of patients; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; CLL, chronic lymphocytic leukemia; SAA, severe aplastic anemia; MDS, myelodysplastic syndrome; GVHD, graft-versus-host disease.
Proportion of the entire patient sample.
P = .035 (one-tailed) for the likelihood of receiving a 3-Ag rejection mismatched graft for high-risk versus low-risk category.
P = .131 (one-tailed) for likelihood of receiving a 3-Ag GVHD mismatched graft for high-risk versus low-risk category.